511 Therapeutics, Inc. — SEC Form D Filing

511 Therapeutics, Inc. filed an SEC Form D on October 30, 2026, reporting $500K raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
October 30, 2026
Amount reported
$500K
Round stage
Pre-seed due to the $500,000 funding round intended for initial preclinical target validation and early lab operations.
Industry
Biotechnology
Website
https://www.511therapeutics.com

What the company does

Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffering from refractory genetic and metabolic disorders lack targeted molecular therapies that treat underlying root biological causes rather than managing superficial symptoms.

Solution

511 Therapeutics discovers and develops novel targeted biopharmaceutical therapeutics designed to modify disease pathways and improve long-term patient outcomes.

Why now

Advances in high-throughput genomic screening and computational drug design enable early-stage biotechnology startups to identify high-affinity therapeutic candidates rapidly with minimal initial preclinical capital.

Source: SEC EDGAR Form D filing